Assure Holdings Corp. (NASDAQ:IONM) Q4 2022 Earnings Call Transcript

Assure Holdings Corp. (NASDAQ:IONM) Q4 2022 Earnings Call Transcript April 3, 2023

Operator: Good day, everyone, and welcome to the Assure Holdings Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. Please note, this call may be recorded. It is now my pleasure to turn today’s program over to Brett Maas, Investor Relations Manager. Please go ahead.

Brett Maas: Hello, everyone. Thank you for participating in today’s conference call to discuss Assure Holdings’ financial results for the fourth quarter and full-year 2022. On the call today are Executive Chairman and CEO, John Farlinger; and CFO, John Price. Pre-market this morning, the company issued a press release announcing its results. The release is available in the Investors section of our website. Before we begin the prepared remarks, I’d like to remind that some of the statements made will be forward-looking and are made under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected or implied due to a variety of factors. We refer you to Assure’s recent filings with the SEC, including our annual report on Form 10-K for the full year for a more detailed discussion of the risks that could impact the company’s future operating results and financial condition.

Also on today’s call, management will reference certain non-GAAP financial measures, which we believe provide useful information to investors. For a reconciliation of these non-GAAP measures, please consult the most recently filed 8-K associated with the filing of the earnings release for the year ended December 31, 2022, which is available on SEC’s website. Finally, I would like to remind everyone who dialed into the call by telephone, you may want to join our webcast and this call will be recorded and made available for replay via link and on the company’s website. Now, I’d like to turn the call over to Executive Chairman and CEO of Assure Holdings, John Farlinger. John?

John Farlinger: Thank you, Brett. Hello, everyone, and thanks for joining us today. We’re obviously disappointed by year-end results. However, a lot more elaboration is needed to get clarity on the position of our business at the current time. We finished 2022 with a managed case volume of 21,557, well within our guidance, and expectations for between 21,000 and 22,000 managed procedures. This represents an increase of 24% in managed case volume over last year, a compelling metric to the underlying strength of our business. During 2022, we provided oversight to over 14,000 surgeries. There continues to be strong demand for our services. Interoperative neuromonitoring is essential for invasive surgeries that place the nervous system at risk.

It is a standard of care, and surgeons agree it is a vital resource in the operating room. Importantly, our business remains highly scalable, with compelling unit economics, despite what have been significant reimbursement challenges that are plaguing not only the interoperative neuromonitoring industry, but the larger healthcare industry in general. We’re taking the actions necessary to counterbalance a challenging reimbursement landscape by exiting the shared revenue MSA model, utilizing our internal RCA function, and greatly accelerating our cash collections from commercial payers, facilities, and patients. And further, we are continuing to reduce our cost of delivery by leveraging our tele-neurology services. On the revenue side, we made the prudent decision to implement a new accounts receivable, accrual, and reserve strategy during 2022.

Our new accounting estimation practice reserves and writes down claims earlier in the accounts receivable aging process. This led to a much higher accounts receivable reserve in 2022, which negatively impacted our net revenue. Recorded gross revenue of approximately $28.9 million. A bad debt charge of $17.9 million resulted in net revenues of $11 million for the year end ending December 31, 2022. A number of factors led to this reserve. During 2022, we experienced a more than 60% decrease in the Texas State arbitration rate beginning in October, which not only negatively impacted our accrual rate, but also increased our accounts receivable reserve. Additionally, collections on the COVID period during 2020, these claims were negligible, also increasing our bad debt expense.

All the while, our company continued to experience accelerated cash receipts, collecting $21 million in 2022 compared to $13 million to 2021, and reducing our days to collect to 105 in 2022 compared to 209 in 2021. We’re taking a pragmatic approach to accounts receivable reserves, given the challenges associated with collecting certain receivables, and persistent industry headwinds. Using this approach, we’ve increased visibility and substantially reduced our risk of future write-downs for uncollectible accounts going forward. The reimbursement environment was challenging in 2022, to say the least, and served as a significant negative factor for our financial results. It impacted our topline revenue, our profitability per case, and our margins.

For federal reimbursements, the time from submission to resolution continues to be extremely long. The federal No Surprises legislation, which went into effect in January of 2022, was passed with the best of intentions, to protect consumers and provide healthcare providers with the ability to arbitrate claims where service was performed, but a fair rate was not paid. However, implementation of the legislation has been an utter failure on the part of the federal governments, as the federal agencies have faced numerous operational challenges, including a significantly higher number of claims than anticipated, which has led to lengthy times to resolve outstanding claims, and this is rampant across the entire healthcare industry. To date, we have filed nearly 400 claims under this legislation.

Just last month, we had our first case adjudicated. While the results are positive, it is anecdotal, until we process more cases through the federal bottleneck. While the time from submission to resolution is consistently longer than the 90 days prescribed by the legislation, seven months was what it took for our first case. We are encouraged by this first win. We expect to file an increasing number of federal arbitration cases in 2023. The resolution of these claims in a timely manner will have an impact on future profitability and cash flow. For State reimbursements, there was a significant reduction in benchmark reimbursement rates that went into effect in October, and there have been a number of challenging technical issues surrounding the inbound filing of claims.

We believe the commercial insurance companies are lobbying in certain States to secure reduced reimbursement rates, causing downward pressure on our accrual rates. The gamesmanship that surrounds provider reimbursement is a cloud over the entire industry. Just recently, one of our private equity-backed competitors was forced to shut its doors. This was a competitor that had been in business for much longer than Assure. The reimbursement environment further supports our decision to develop internal revenue cycle management resources, which continue to be critical to our business. Smaller competitors that rely on third party billing companies are vulnerable to the current turmoil surrounding federal and State reimbursements, primarily because they don’t have a framework on the tools to analyze the data or arbitrate like we do.

Photo by JESHOOTS.COM on Unsplash

We have developed a more data-driven analytical approach to understanding and managing our revenue cycle and reimbursement per case. We believe that this remains a key differentiator in our business. Consistent success in arbitration is essential, and you need the data and analytics to win cases and be successful. We believe the arbitration process will ultimately lead to in-network contractual agreements with commercial insurance payers, which in turn will speed up cash flow and improve participation ranks. There is a strengthening case for industry consolidation in the near-term, and we expect to selectively pursue M&A opportunities that will help us to expand our managed case volume in 2023 2022, we extended our geographical reach to include the state of New Jersey, which historically has had a strong reimbursement profile, being among the top five in the United States.

2023, we are looking to add business in this new market, as well as expand in high-performing markets like Texas and Colorado, where we already have a significant footprint. On the cost side, in February this year, we initiated an incremental cost reduction plan that targets a further $2 million reduction in annualized operating costs. The element to this plan include a reduction in salaries for current staff, and a reduction in headcount. We expect the impact of this plan will become more evident in our financial results beginning in the second quarter of fiscal 2023. This plan is in addition to the more than $4 million in salary and workforce reductions, as well as other costs, that was introduced earlier in 2022. While the industry is facing a number of challenges, we are optimistic we will overcome all these hurdles in 2023.

We have a robust infrastructure of professionals, capital equipment, and processes that serve the interoperative neuromonitoring space well, and data analytics on the back end to help us manage and improve our revenue cycle management process. Through cost-cutting and the use of analytics, we are positioned to withstand the industry challenges around reimbursement, and achieve sustained profitability and cash flow from operations during the second half of 2023. We are right-sizing our business to be a self-sustaining operation. Again, interoperative neuromonitoring is essential for invasive surgeries that place the nervous system at risk, and is a vital resource in the operating room. The demand is still there. I want to point out that notwithstanding the issues around the reserve, our total cash collected has steadily increased the trailing six, 12, and 24-month period basis.

We continue to experience strong cash collections and collected $21 million in 2022 compared to $13.4 million in 2021. Total cash collections, including MSA collections, were $27.5 million in 2022 compared to $22.7 million in 2021. We would further benefit from in-network agreements, which we anticipate to achieve during 2023. Additionally, we are no longer supporting managed services agreements, required revenue shares with our surgeon partners, and we have exited the majority of these business agreements and expect to fully exit by the second quarter of 2023. As a result, we anticipate achieving and collecting an additional $200,000 or more of incremental cash receipts per month as a result of controlling all of that cash flow that is currently shared under MSAs. Importantly, we are driving higher participation rates, shortening our cash cycle, and achieving better collections.

We have built a sophisticated data-driven revenue cycle management function that is continuing to improve collections and improve our visibility into the market. We’re off to an encouraging start in 2023, with first quarter revenue collections better than our internal forecast, and headed toward what we believe will be measurable improvement. The percentage of first-pass payment rates has been increasing. Days to pay have been reduced, and commercial payers are paying at a higher rate versus last year. While still early in the year, reimbursement rates appear to be stabilizing and possibly rebounding from 2022, and we are moving closer toward receiving a fair rate for the services we provide. Looking ahead, we are focused on aligning our costs with updated management case revenue expectations, and adding scale in favorable markets, and fixing, controlling, and reducing the cost of delivering our services.

Next, John Price will walk us through the full-year financials. John.

John Price: Thanks John, and thank you, everyone, for joining us today. We continue to grow our procedure count, performing approximately 5,400 managed cases during the fourth quarter, an increase over the prior year’s fourth quarter, and bringing our total for the year to 21,557. The fourth quarter is typically a seasonally strong quarter in our business, and we experienced a more beneficial revenue mix, with a higher proportion of patients utilizing more profitable commercial insurance programs relative to the proportion of facility patients. As a reminder, we exited the underperforming markets of Louisiana and Nevada during 2022. For the full year, we reported gross revenue of $28.9 million and net revenue of $11 million.

Net loss was $30.7 million. Adjusted EBITDA loss was $18.5 million. Our gross revenue was negatively impacted by implicit price concessions of $17.9 million related to age claims, and a change in accrual rates from downward pressure on reimbursement. Based on our historical experience, claims generally become uncollectible once they are aged greater than 24 months. As such, our implicit price concessions include an estimate of the likelihood that a portion of our accounts receivable may become uncollectible due to age. As John discussed, we refined our accounts receivable reserve process that now takes a more conservative approach to AR reserves. As a result, we begin to build a valuation reserve against claims earlier in the aging process.

This process led to a significantly higher AR reserve in 2022, which negatively impacted our financial results, and made for a challenging comparison to the prior year. At December 31, 2022, the total accounts receivable reserve was approximately $14 million, and represents nearly 50% of our outstanding gross accounts receivable. Looking ahead, we expect a more normalized cadence to our accounts receivable reserve, and are forecasting less than $2 million of reserves for the first quarter of 2023. As John mentioned, we began to experience a decline in our reimbursement rates starting in October €˜22, due to a revision in the Texas State benchmark, which negatively impacted revenue by $3.7 million for the year. This led to a lowered expectation in payments in our largest market, and lower accrual rate, hence driving down revenue.

Cost of revenues for 2022 were $15.2 million compared to $14.3 million for 2021, an increase of 6%. Importantly though, the number of managed cases increased 24% year-over-year. Through our cost-cutting measures, benefit of scale in the business from the growth and volume in tele-neurology services, we reduced our cost of delivery. In 2023, we are focused on further reducing our average cost of delivery and drive further improvement in gross margin. Operating expenses for 2022 were $23.6 million and include non-cash goodwill impairment charge of $3.5 million. Additionally, we amended the useful life of certain intangible assets, resulting in an additional $3.1 million of non-cash amortization expense. When excluding these charges, normalized operating expenses were $17 million, which is nearly flat compared to 2021.

Management will continue to evaluate our goodwill balance and anticipates a further impairment of goodwill of $1 million in the first quarter 2023. We collected approximately $21 million of cash in 2022 compared to $13.4 million in 2021. Further, we continued to experience improvement in our average days to collect to 105 days in 2022 from 209 days in 2021, an important operating metric when measuring revenue cycle and use of working capital. At December 31, 2022, 86% of our outstanding accounts receivable was aged 12 months or less from date of service. In comparison, during the first quarter of 2022, just 68% of accounts receivable was part of the same category. A much larger portion of our accounts receivable are more current, which reduces our exposure and risk to future reserves.

I’ll pass the call back over to John Farlinger for the first quarter and full year 2023 expectations. John?

John Farlinger: Thank you, John. This is certainly a challenging business and a challenging industry. And now understanding the significant impact of downward reimbursement pressures, the company does have a number of things to be positive about. Firstly, cash collections exceeded $21 million in 2022, and we expect them to be strong in 2023. Total system-wide collections were a record $27.5 million. Secondly, our plan is to be out of the MSA revenue sharing agreements by the end of the second quarter of 2023, with over 70% of the remaining MSA volume becoming wholly owned by the end of the second quarter. Thirdly, we have shut down the number of unprofitable markets, which will not be agreed on cash in 2023. Fourthly, the certainty of what we will recover on revenue being realized in the cash collections, is now much more certain, and there could be upside coming out of the federal arbitration process as it starts to take effect in 2023.

Fifthly, we’re involved in two pieces of outstanding litigation in Louisiana during the course of 2023, with the first going to trial in July. These could have a material impact on our cash position over the balance of the year. Further, we are finalizing our employer retention credit, an expected meaningful amount to be recovered from the IRS. This is a potential seven figure recovery and will be filed over the next 10 days. We’ve historically been very successful in recovery incentives and monies from the federal government over the past three years. We’ll continue to focus on driving our cost of delivery to less than $1,100 per patient, including the cost of our RCM function so that we can meet the demands of lower reimbursement. So, with that, I’ll turn the call back over to the operator for Q&A.

Thank you.

See also 15 Most Powerful Countries in Asia in 2023 and Cathie Wood’s Stock Portfolio: 2023 Stock Picks.

Q&A Session

Operator: Thank you. The first question is coming from Jim Sidoti from Sidoti & Company. Jim, your line is live.

Jim Sidoti: Hi, good morning. Thanks for taking the questions. So, if you look at the $15 million of accounts receivables on the balance sheet today, or I’m sorry, at the end of the year, how confident are you that you’ll be able to collect those receivables?

John Farlinger: John Price, do you want to answer that question?

John Price: On the call. We revised our practice of estimating the bad debt, and we’ve talked about this on some of the other calls over the course of 2022, where we started the reserve accounts receivable earlier in the process, which ultimately more expense rolled through the 2022 financials. And we think we’re in a really good spot at this point to address the bad debt and potential write-offs as we go forward. And you can see that in the forecast. For Q1, we’re anticipating less than $2 million of bad debt, and we’ve really reduced our exposure on a go forward basis.

John Farlinger: And Jim, I think – I’m sorry, John. I think the key issue from our standpoint, we’ve significantly reduced the amount per claim that we’re going to obtain here. And you’ve got other data points now. You’ve got state arbitrations. You’re probably going to have federal claims coming through now, and we’ve written off so much that we don’t think there’s a lot of downside on the accrual rates now. So, the only other issue is, and then can you collect the money on a per claim basis. So, we’re feeling pretty good about that. In fact, there may be some upside going forward. The other thing is on our accounts receivable, there is also an MSA accounts receivable number. That is going to go away. As we we’ve struck deals with our surgeon partners, we will take over a meaningful amount of that accounts receivable as well to collect on a go-forward.

Jim Sidoti: Okay. Can you talk about what you expect for procedure rates in the first quarter and then to 2023?

John Farlinger: Yes, I think again, here’s the one problem we have so far. We’ve got hundreds of claims in queue through the IBR process under the No Surprise Act. We have very little date on that. But based on the information we have, we think a commercial claim will be worth probably between $22,000 and $2,400, in some cases higher. But that’s probably in the range of where we are going to settle right now, down significantly from a year ago at this time, and probably down by 50% from where we were two years ago. And that’s forced us to run much, much lean. And John talked about where we brought the cost of delivery down, and we brought it probably down by about 30% to 40% or more in most States. And we’ve shut down States where we are not making margin in an attempt to conserve cash and become profitable in the very short term.

Jim Sidoti: Okay. And then how about in terms of number of procedures? You did a little over $5 million in the fourth quarter, and that’s with exiting Louisiana and Arizona. How many procedures do you expect to have completed at the end of Q1 and how many for the year?

John Farlinger: Q1 will be – is always our softest quarter. It is every year. I think we’re looking at about 15% to 20% growth. That’s what we’re targeting this year in terms of procedure growth.

Jim Sidoti: Okay. And that’s for the quarter and for the year?

John Farlinger: For the quarter, yes, it’s probably going to be – it will be similar to last year. The only thing I would say is, we have the benefit of an acquisition that we made in the last day of December, adding about 1,400 surgeries annually. So, that will certainly help us get off to a better start and a faster start in 2023 and give us additional volume.